AstraZeneca launches pilot program for Cordio Medical’s AI heart failure app

2023-05-19

AstraZeneca and the Bellvitge University Hospital plan to launch the first pilot program for the Cordio Medical HearO app. The HearO smartphone app provides widespread access to medical-grade technology for patients with congestive heart failure (CHF). It enables the patient to monitor symptoms, manage treatment and improve quality of life. Astrazeneca said the pilot program aims to assess the feasibility of using the app to monitor CHF patients. The monitoring takes place in both the hospital and at-home settings. It includes tracking HearO’s success rate of patient compliance and its ability to issue notices prior to heart failure events. The study takes place over a 6-9 month period. Previous and ongoing studies in Israel and the U.S. tested and validated the technology. Those demonstrated an 82% success rate in predicting a heart decompensation event up to 22 days before the occurrence. Astrazeneca and Cordio are “blazing a trail” “The pilot aims to familiarize cardiologists, nurses, and patients with the medical-grade digital system,” said Tamir Tal, CEO of Cordio Medical. “As leaders in digital health, Hospital Bellvitge and AstraZeneca are blazing a trail for other healthcare providers to efficiently implement the HearO app across unique healthcare systems.” HearO, a first-of-its-kind AI voice biomarker solution, monitors patients’ unique speech patterns. It detects warning signs of worsening or possible complications. The advanced algorithmic technology offers a cost-effective, easy-to-use tool that enables the detection of CHF patients’ symptoms before they appear. This enables doctors to optimize patient-specific treatment plans. “AstraZeneca is committed to advancing digital tools to diagnose, monitor and treat high-impact pathologies such as heart failure,” highlights César Velasco, director of Innovation and Digital Strategy at AstraZeneca. “Thanks to the collaboration across Spanish hospitals and health professionals, we are closer to making life-saving digital health tools a reality for millions with chronic diseases.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构